119th Congress
H.R. 10857
To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Jake Auchincloss(D-MA)
- Introduced
- Oct 22, 2026
- Committees
- House Committee on Energy and Commerce;House Committee on Ways and Means
- Official text
- Congress.gov · Congress.gov page
Cosponsors (1)
Original cosponsors (1)
- H. Morgan Griffith (R-VA)
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Latest action(Oct 22, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Roll-call votes
No recorded votes on this bill.
Actions
- Oct 22, 2026 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. - Oct 22, 2026
Introduced in House